Members Login
ACTG Network
  • Home
  • About
    • About the ACTG
    • Leadership and Organizational Matrix
    • ACTG Committees and Centers
    • Underrepresented Populations
    • Contact the LOC
  • Clinical Trials
    • About the Clinical Trials Process
    • Active Clinical Trials
    • Clinical Trials Resources
    • Study Result Slides
  • Sites
  • Community
    • Global Community Advisory Board
    • Community Resources
    • They Became My Family
  • Publications
  • News
    • In Memorium
    • Press Releases & Announcements
    • Newsletters
  • For Researchers
    • Submit a Proposal
    • Small Clinical Trials RFA –HIV Remission & Cure
    • Specimen Repository Website
    • HIV Databases

University of Pittsburgh CRS

Location

AIDS Clinical Trials Unit, 740 Falk Medical Building, 7th Floor, 200 Lothrop Street
Pittsburgh, PA 15213
United States of America

Phone412-647-0771
CRS Coordinator

Renee Weinman
drw38@pitt.edu
412-383-1748

CRS Leader

Sharon Riddler
riddler@pitt.edu
412-383-1741

Studies
  • A5128: US Genomic Sampling
  • A5321: Decay of HIV-1 Reservoirs in Participants on Long-Term Antiretroviral Therapy: The ACTG HIV Reservoirs Cohort (AHRC) Study
  • A5354: Early ART in Acute HIV
  • A5359: The LATITUDE Study
  • A5377: Tri-specific Antibody
  • A5357: A Study of Long-Acting Cabotegravir Plus VRC01LS to Maintain Viral Suppression in HIV-1-Infected Adults
  • A5368:Anti-PD-1 Antibody in HBV Infected on Suppressive Antiviral Therapy
  • A5366: Selective Estrogen Receptor Modulators to Enhance the Efficacy of Viral Reactivation with Histone Deacetylase Inhibitors
  • A5361s: Pitavastatin to REduce Physical Function Impairment and FRailty in HIV (PREPARE)
  • A5332: REPRIEVE Trial
  • A5322: Long-Term Follow-up of Older HIV-infected Adults in the ACTG: Addressing Issues of Aging, HIV Infection and Inflammation (HAILO)
  • A5401: ACTIV-2 Outpatient Monoclonal Antibodies and Other Therapies
  • A5379: B-Enhancement of HBV vaccination in persons living with HIV (BEe-HIVe): Evaluation of HEPLISAV-B
  • A5391: Doravirine for Persons with Excessive Weight Gain on Integrase Inhibitors and Tenofovir Alafenamide (The Do IT Study)

Mission

The mission of the ACTG Network
is to cure HIV and reduce the
burden of disease due to HIV
and its complications, including
tuberculosis and viral hepatitis.

Useful Links

Government Resources
Clinical Trials Resources
Grants and Contracts
New Members

© ACTG. All Rights Reserved. | admin login